Second Sight Receives FDA Approval to Begin Feasibility Study of Orion Cortical Visual Prosthesis System

September 1, 2017: By Joan McKenna

Second SightSecond Sight, maker of the Argus II retinal prosthesis system, announced Aug. 28 that it has received conditional approval from the US FDA to begin a feasibility study of its Orion Cortical Visual Prosthesis System.

The Sylmar, California, company may enroll up to five patients in total at two US sites: the University of California at Los Angeles and Baylor College of Medicine in Houston. The FDA has requested that the firm conduct additional device testing and address outstanding questions within 45 days.

Will McGuire, president and CEO of Second Sight, said in a statement: “The Orion team has met all major internal milestones this year, and we remain on track to achieve the company’s stated goal of implanting our first Orion patient before year end.”

Second Sight’s Orion is designed to convert images captured by a miniature video camera mounted on the patient’s glasses into a series of small electrical pulses. The Orion transmits these electrical pulses wirelessly to an array of electrodes implanted on the surface of the visual cortex. By bypassing the retina and optic nerve and directly stimulating the visual cortex, a cortical prosthesis system has the potential to restore useful vision to patients blinded due to many reasons, including glaucoma, diabetic retinopathy, or forms of cancer and trauma, the company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023